Clinical trial
Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus…
NCT00490711 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00490711 |
|---|---|
| Title | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer |
| Official title | Phase II Study of Sequential Therapy With Paclitaxel Plus Carboplatin Followed by Gemzar Plus Carboplatin in the Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages III-IV |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, carboplatin, paclitaxel |
| Enrollment | 7 |
| Start date | Jul 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Jun 25, 2007 |
| Last update posted | Jun 25, 2007 |
| Countries | Slovakia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: